Paulina Giacomelli

Dr. Paulina Giacomelli

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
PGPaulina Giacomelli
Paulina Giacomelli
BMBrendan Martin
Brendan Martin
JMJason Markle
Jason Markle
CWChristopher Williams
Christopher Williams
NHNicholas Hooper
Nicholas Hooper
JPJohn Pitts
John Pitts
Background/Objectives: Platelet-rich plasma (PRP) preparations vary widely, and most studies report concentration rather than absolute platelet dose, limiting cross-study comparison. This review provides an evidence-informed synthesis of platelet dose, concentration, and injectate volume in knee, hip, and glenohumeral osteoarthritis (OA). Methods: A PubMed-based narrative review included 26 primary studies (16 knee, nine hip, and one glenohumeral); systematic reviews provided context. Dose was classified as directly reported, calculated from measured product characteristics, nominally estimated, or assumption-dependent/unverifiable. Assumption-dependent values were excluded from numerical ranges. Randomized trials were assessed with the Cochrane Risk of Bias 2 tool. Results: Knee OA provided the strongest dose-related evidence. Reported, calculated, or aggregate study-level dose estimates ranged from approximately 2.5 to 13.7 billion platelets per injection, with findings suggesting a dose-related signal at approximately 5 billion platelets or greater. In hip OA, measured protocols associated with clinical improvement delivered approximately 6.2–7.0 billion platelets per injection. Glenohumeral evidence was limited to one trial. However, overall, the available evidence did not establish validated minimum or optimal dose thresholds. Conclusions: In knee OA, the available literature shows a dose-related signal at approximately 5 billion platelets or greater per injection, while hip studies report measured protocols around 6–7 billion platelets per injection. These findings are descriptive rather than prescriptive and do not establish clinical dosing thresholds or recommendations. Glenohumeral evidence remains insufficient for dose-specific conclusions.